• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2016 Fiscal Year Final Research Report

Driver and druggable oncogene aberrations in KRAS mutation-negative pancreatic ductal adenocarcinoma

Research Project

  • PDF
Project/Area Number 26461039
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Gastroenterology
Research InstitutionNational Cancer Center Japan

Principal Investigator

Ueno Hideki  国立研究開発法人国立がん研究センター, 中央病院, 医長 (10307522)

Project Period (FY) 2014-04-01 – 2017-03-31
Keywords膵がん / 遺伝子融合 / 治療標的 / KRAS遺伝子変異
Outline of Final Research Achievements

Oncogenic mutations in the KRAS gene are a well-known driver event, occurring in >95% of pancreatic cancers. The objective of this study was to identify driver oncogene aberrations in pancreatic cancers without the KRAS mutation. Whole exome and transcriptome sequencing was performed on four cases of KRAS mutation-negative pancreatic ductal adenocarcinoma, which were identified in a cohort of 100 cases. One case harbored an oncogenic DCTN1 (dynactin 1)-ALK fusion. The fusion gene enabled IL-3-independent growth of Ba/F3 cells and rendered them susceptible to the ALK tyrosine kinase inhibitors crizotinib and alectinib. Another case harbored an oncogenic RRAS mutation that activated the GTPase of the RRAS protein. The results suggest that rare oncogenic aberrations, such as the ALK fusion and RRAS mutation, drive pancreatic carcinogenesis independent of the KRAS mutation and can be a therapeutic target.

Free Research Field

がん遺伝学

URL: 

Published: 2018-03-22  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi